Loading...
StocksRunner logo
 
 
BioNTech
109.60
-0.23%
 
BNTX BioNTech
Last Price
Change
109.60
 
-0.23%
 
 
 

 
Sentiment
 
  Login to display
 
 

111.72

129.94

143.41

134.04

 
 
1m
3m
6m
1y
 

Summary

  Login to display BioNTech (BNTX) recommendation from the last 90 days from financial news and social media.
 

Strengths

Rewards

 Upgraded on attractively valued

 

Risk Analysis

Risk Analysis

 Analysts lowered price target

 
 

Risk Level

 
StocksRunner
 

BioNTech (BNTX) has Moderate Risk Level

Click here to check what is your level of risk

 

Analysts Opinion

Click on the category for more information
 
 

Earnings

×
 

Earnings

2.50
 

StocksRunner

 Revenue declined YoY

StocksRunner

 Earnings decline YoY

StocksRunner

 Above analyst estimates

StocksRunner

 Reported a weak earnings

 
 

Rating

×
 

Rating

NA
 

StocksRunner

 Upgraded on attractively valued

 

Momentum

×
 

Momentum

2.00
 

StocksRunner

 Price value has negative momentum

 

Activity

×
 

Activity

3.69
 
 

Future

×
 

Future

1.00
 

StocksRunner

 Analysts lowered price target

 
 

Analysts Opinion

Analysts opinion is negative and it remained unchanged from the past 3 months

 

Street Consensus

Buy
Opinion
Trend
Score
Potential
Score
 
63%
NA
0%
0%
 
On Track
On Track
On Track
 

Street Opinion 

Street view is bullish but have mixed views on the near-term outlook

 
Events Rating
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 
Positive vs Negative
 
63%
37%
Positive
Negative
12 out of 19
events present
7 out of 19
events present
 

 
Events Calendar
Click for more information
 
May
S
M
T
W
T
F
S
June
S
M
T
W
T
F
S
 
Highlights
Last
Modify
Closing
Price
%
Change

 
Weak Earnings
2 Month Ago
107.93
-0.46%
 
Price Target Lowered
2 Month Ago
127.71
-0.92%
 
Similar Peers
Score
Closing
Price
%
Change

NVAX

Novavax

2.25

7.67

+6.02%

 

MRNA

Moderna

3.38

125.58

-1.04%

 
 
Top Headlines

biontech (bntx) up on initial data from lung cancer antibody. biontech&rsquo.sbntx shares rose almost 4% on jun 2. this occurred soon after interim data from an ongoing phase i/ii study on its

Mon Jun 5, 2023

Activity

why shares of biontech rose friday. what happened shares of biontech (nasdaq: bntx) were up as by much as 5.3% on friday before closing the session up 3.85% after the biotech company announced positive news regarding a clinical trial for its no

Fri Jun 2, 2023

Activity

biontech reports promising data on bnt316 phase 3 trial slated for q3.

Fri Jun 2, 2023

Activity

biontechs oncoc4 partnership off to good start with mid-stage trial results. biontech said on friday that a new cancer immunotherapy candidate that it is working on with United States partner oncoc4 inc was shown to shrink tumours in close to 30

Fri Jun 2, 2023

Activity

amended european deal for biontech-pfizers covid-19 vaccines allows reduced purchases. the european commission (ec) hadwith) and

Fri May 26, 2023

Activity

curevac files expanded patent lawsuit against pfizer/biontech over mrna technology. curevac nv said on friday it had filed an expanded patent infringement claim against pfizer inc and biontech over the use of mrna technology and that a United St

Fri May 19, 2023

Activity

earnings scheduled for may 8 2023. &. hni (nyse:) is likely to report quarterly loss at $0.03 per share on revenue of $462.26 million. &. axsome therapeutics (nasdaq:) is projected to report quarterly loss at $1.04 per share on revenue of $26.07 million.

Mon May 8, 2023

Earnings

biontech revenue falls. why the stock is climbing anyway..

Mon May 8, 2023

Earnings

biontech earnings drops on lower covid vaccine sales. biontech pfizers partner on covid-19 vaccines said first-quarter net income plunged on lower demand for the shots as the german biotech firm broadens its attention on cancer and other infecti

Mon May 8, 2023

Activity
Momentum

cash-rich biontech broadens scope as covid shot sales slide. germanys biontech pfizers partner on covid-19 vaccines said on monday its first-quarter net income plunged on lower demand for the shots as it widens its work on cancer and other disea

Mon May 8, 2023

Activity

biontech q1 net profit declines. reiterates 2023 covid-19 vaccine revenue guidance. (rttnews) - biontech se (bntx) said its financial performance has been fully in line with the companys expectations for the first quarter of 2023. commercial rev

Mon May 8, 2023

Activity
Earnings

biontech beats q1 top and bottom line estimates. reaffirms fy23 outlook.

Mon May 8, 2023

Earnings

european unions amended covid-19 vaccine deal with pfizer-biontech: near-monopoly status potential threat to rivals. the european union bloc is reportedly negotiating an amended deal with) and) for around 70 million covid-19 vaccine doses despite the euro

Mon May 1, 2023

Activity

wuxi biologics and wuxi xdc congratulate dualitybio on entering global licensing and collaboration agreements with biontech to accelerate development of differentiated antibody-drug conjugate therapeutics.

Mon Apr 17, 2023

Activity

biontech stock price target cut to $128 from $142 at j.p. morgan. this is a real-time headline. these are breaking news delivered the minute it happens delivered ticker-tape style. visit www.marketwatch.com or the e page for more information about this br

Mon Apr 10, 2023

Potential

 
 
 
StocksRunner

Get all the pieces of the puzzle on important data activity before the major news sources break the story and find out what happening right now and what could happen in the future

FIND US ON

StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss
 

Receive our daily BNTX alerts

Enter your email to receive daily alerts

 
Home

Leading Gainers

Upgrades

Downgrades

Top Leaders

 
Categories

Ipo's

Dividend

Option Activity

Insiders Activity

Institutional Holdings

 
Tags

New Products

FDA Approvals

Agreements

Financial Reports

 
About Us

Log In

Sign Up

Contact Us

Terms of use

Privacy Policy

 
 

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
StocksRunner

StocksRunner

Get the pulse of the market

 
StocksRunner

BNTX BioNTech

Last Price
109.60
Change
-0.23%
 

Summary

  Login to display BioNTech (BNTX) recommendation from the last 90 days from financial news and social media.

 
 
111.72
129.94
143.41
134.04
 
 
1m
3m
6m
1y
 
Sentiment
 

  Login to display

Strengths

Rewards

 Upgraded on attractively valued

Risk Analysis

Risk Analysis

 Analysts lowered price target

 
 
 
 
Street Consensus
 
Buy
Opinion
Trend
Score
Potential
Score
 
NA
0%
0%
On Track
On Track
On Track
 
63%
37%
Positive
Negative
12 out of 19
events present
7 out of 19
events present
 

Street Opinion

Street view is bullish but have mixed views on the near-term outlook

 
 
Analysts Opinion
Hover the category for more information
 
 

Earnings

×
 

Earnings

2.50
 

StocksRunner

 Revenue declined YoY

StocksRunner

 Earnings decline YoY

StocksRunner

 Above analyst estimates

StocksRunner

 Reported a weak earnings

 
 

Rating

×
 

Rating

NA
 

StocksRunner

 Upgraded on attractively valued

 

Momentum

×
 

Momentum

2.00
 

StocksRunner

 Price value has negative momentum

 

Activity

×
 

Activity

3.69
 
 

Future

×
 

Future

1.00
 

StocksRunner

 Analysts lowered price target

 
 

Analysts Opinion

Analysts opinion is negative and it remained unchanged from the past 3 months

 
 
 
 
 
Events Rating
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 
 
Risk Level
 
StocksRunner
 

BioNTech (BNTX) has Moderate Risk Level.  Click here to check what is your level of risk

 
 
 

Events Calendar

Hover for information

 
May
 
S
M
T
W
T
F
S
 
June
 
S
M
T
W
T
F
S
 
 
 
 
Highlights
Last
Modify
Closing
Price
%
Change

 
Weak Earnings
2 Month Ago
107.93
-0.46%
 
Price Target Lowered
2 Month Ago
127.71
-0.92%
 
 
Similar Peers
Score
Closing
Price
%
Change

NVAX

Novavax

2.25

7.67

+6.02%

 

MRNA

Moderna

3.38

125.58

-1.04%

 
 
 
 
StocksRunner

Get all the pieces of the puzzle on important data activity before the major news sources break the story and find out what happening right now and what could happen in the future

FIND US ON

StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss

 

Receive our daily BNTX Alerts

Enter your email to receive daily alerts

 
Home

Leading Gainers

Upgrades

Downgrades

Top Leaders

Categories

Ipo's

Dividend

Option Activity

Insiders Activity

Institutional Holdings

Tags

New Products

FDA Approvals

Agreements

Financial Reports

 
 

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
 
 
 

Top Headlines